Compared to control IgG, treatment with anti-PD-1 therapy had limited effect on tumor formation and progression (Fig. 1A-B), indicating that murine iCCAs have poor response to anti-PD-1 monotherapy. This evidence concerns the gene PDCD1 and neoplasm.